ClinicalTrials.gg
RecruitingNCT07856420Updated Nov 3, 2026

A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment

A Phase 3 interventional study of JNJ-99245354 and Placebo in Generalized Anxiety Disorder, sponsored by Intra-Cellular Therapies, Inc.. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Nov 3, 2026Now RecruitingFirst site in United States+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
705
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 265 studies in Generalized Anxiety Disorder with a site in United States — 38 open to participants now, 53 under way, 9 of them phase 3. Generalized Anxiety Disorder · United States.

Planned enrollment
10th of 234
705 · median 90
Started
2026
with 14 others
Phase 3
45 of 265
6 open now
Primary completion
2030-09
later than 51 of 52 live
Registered
264th of 265
by date

Among the 265 studies in Generalized Anxiety Disorder with a site in United States, this one is the 10th largest by planned enrollment of the 234 interventional ones that give a count, is one of 15 that started in 2026, is one of 45 in phase 3, reaches primary completion later than 51 of the 52 other live ones, and was the 264th registered.

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

Browse Generalized Anxiety Disorder studies →

Open to participants now

38 of the 265 studies in Generalized Anxiety Disorder with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Generalized Anxiety Disorder studies recruiting now, 32 (37%) set no upper age limit and 52 (60%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Generalized Anxiety Disorder with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess if JNJ-99245354 administered once daily works better to reduce anxiety compared to placebo when given as an additional (adjunctive) therapy in participants with generalized anxiety disorder (GAD; a mental health condition defined by uncontrollable, and excessive worry about everyday events for a long period of time).

03

Conditions studied

  • Generalized Anxiety Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Medically stable on the basis of physical examination, medical history, vital signs, and 12-lead (ECG) performed at screening and at baseline
  • Medically stable on the basis of clinical laboratory tests performed at screening
  • History of inadequate response to at least 1 generalized anxiety disorder (GAD)-approved treatment taken at an adequate dose and duration as specified in the protocol for the treatment of ongoing GAD symptoms
  • Is currently an outpatient and is anticipated to maintain outpatient status for the duration of the double blind (DB) treatment period of the trial
  • (BMI) within the range 19-40 kilogram per meter squared (kg/m\^2) (inclusive)

Exclusion criteria

Exclusion criteria:

  • Within the participant's lifetime, has one of the following confirmed (5th edition) (DSM-5) text revision (TR) psychiatric diagnoses: a. schizophrenia, schizoaffective disorder, schizophreniform disorder or other psychotic disorder; b. bipolar disorder
  • Within 6 months of screening, has a confirmed DSM-5-TR psychiatric diagnosis other than GAD, including: a. other anxiety disorders (except simple phobias and social anxiety disorder); b. moderate or severe alcohol or substance use disorders (excluding nicotine); d. moderate or severe major depressive disorder; e. any other psychiatric condition (except for mild major depressive disorder [MDD]) that has been the main focus of treatment
  • Montgomery-asberg depression rating scale (MADRS) total score greater than (>)18 at screening or baseline
  • Lifetime history of inadequate response to >3 of the approved treatments for GAD at an adequate dose and for an adequate duration
  • The participant is taking more than 1 anti depressive therapy (ADT) or is taking ADT + buspirone at screening, regardless of indication, and is unable or unwilling to discontinue additional ADT (or buspirone) prior to baseline
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
705 participants (estimated)

Study arms

  • Experimental
    JNJ-99245354: Dose 1

    Participants will receive JNJ-99245354 dose 1 as an adjunctive therapy once daily for up to 6 weeks in the double blind (DB) period. Eligible participants can enter the open-label (OL) period, to receive JNJ-99245354 dose 1 or dose 2 for up to 24 weeks.

    Drug: JNJ-99245354

  • Experimental
    JNJ-99245354: Dose 2

    Participants will receive JNJ-99245354 dose 2 as an adjunctive therapy once daily for up to 6 weeks in the DB period. Eligible participants can enter the OL period, to receive JNJ-99245354 dose 1 or dose 2 for up to 24 weeks.

    Drug: JNJ-99245354

  • Placebo comparator
    Placebo

    Participants will receive placebo as an adjunctive therapy once daily for up to 6 weeks in the DB period. Eligible participants can enter the OL period, to receive JNJ-99245354 dose 1 or dose 2 for up to 24 weeks.

    Drug: JNJ-99245354 · Drug: Placebo

Interventions

  • JNJ-99245354 will be administered sublingually.

    Also known as: ITI-1284

  • DrugPlacebo

    Placebo will be administered sublingually.

06

What researchers measure

Primary outcomes

  1. Change from Baseline to End of Week 6 in Hamilton Anxiety Rating (HAM-A) Scale Total Score

    The HAM-A Scale is a clinician-rated scale measuring both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). Each item is rated on a 5-point scale ranging from 0=not present to 4=very severe, disabling symptoms. The HAM-A total score ranges from 0 to 56 where higher score indicates greater severity in anxiety.

    Time frame: Baseline, Week 6

Secondary outcomes

  1. Change from Baseline to the End of Week 6 in Clinical Global Impression-Severity (CGI-S) Anxiety Score

    The CGI-S scale is a standardized assessment tool that the clinician can use to rate the overall severity of illness. The CGI-S asks the clinician: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time? CGI-S is rated on the following seven-point scale: 1=normal, not at all ill; 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill participants. Here, higher score indicates higher symptom severity.

    Time frame: Baseline, Week 6

  2. Change from Baseline to the End of Week 1 in HAM-A Total Score

    The HAM-A Scale is a clinician-rated scale measuring both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). Each item is rated on a 5-point scale ranging from 0=not present to 4=very severe, disabling symptoms. The HAM-A total score ranges from 0 to 56 where higher score indicates greater severity in anxiety.

    Time frame: Baseline, Week 1

07

Study locations

4 of 4 sites recruiting
  • Inland Psychiatric Medical Group Inc
    Temecula, California 92591, United States
    Recruiting
  • Nuovida Research Center
    Miami, Florida 33186, United States
    Recruiting
  • Voltaire Clinical Research
    Springfield, Massachusetts 01103, United States
    Recruiting
  • Fieve Clinical Research Inc
    New York, New York 10017, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Data sharing details ↗ · www.jnj.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Sep 2030, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartActual
Sep 29, 2026
Primary completionEst.
Sep 20, 2030
CompletionEst.
Sep 28, 2030
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 3, 2026
Sites
4 sites added — first site in United States
Show 4 added (4 United States)
  • Inland Psychiatric Medical Group Inc · Temecula, United States
  • Nuovida Research Center · Miami, United States
  • Voltaire Clinical Research · Springfield, United States
  • Fieve Clinical Research Inc · New York, United States
Nov 3, 2026
Start date
Sep 30, 2026→Sep 29, 2026 (actual)
Nov 3, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 2 updates
  1. Nov 3, 2026
    Not yet recruiting→Recruiting
    4 sites added — first site in United States
    Show 4 added (4 United States)
    • Inland Psychiatric Medical Group Inc · Temecula, United States
    • Nuovida Research Center · Miami, United States
    • Voltaire Clinical Research · Springfield, United States
    • Fieve Clinical Research Inc · New York, United States
    Start date Sep 30, 2026→Sep 29, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07856420
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Sep 29, 2026
Primary completion
Sep 20, 2030 (estimated)
Completion
Sep 28, 2030 (estimated)
Last update
Nov 3, 2026

Study contacts

Study Contact
Contact
Participate-In-This-Study1@its.jnj.com
844-434-4210
Intra-Cellular Therapies, Inc. Clinical Trial
study director · Intra-Cellular Therapies, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deulumateperone

Start the discussion